Mark Holterman, MD is a former surgeon at Rush Medical Center that currently applies his expertise in pediatric surgery as a professor at the University of Illinois College of Medicine in Peoria. Prior to his current work, Dr. Mark Holterman served at the Children’s Hospital of Illinois, St Francis Medical Center.While at the Children’s Hospital, Dr. Holterman helped complete the first trachea transplant for a child. Over the course of nine hours, a 32 month old korean toddler received a stem cell engineered trachea. The cutting edge operation also utilized a non-absorbable nanofiber tracheal scaffold and bioreactor from Harvard BioScience and a Biospherix XVIVO cell incubation and processing system.The XVIVO cell incubation and processing system allows the cell structures to be grown and stored through a closed system with closed off hoods and cell incubators. Cell incubators of the system, which is modular in design, are integrated into the hood system to avoid contamination risk and reduce volatility. The system also allows additional cell incubators to be incorporated as needed, and each can be customized depending on the specific cell cultures.For additional information on the XVIVO system, visit www.biospherix.com.
A board-certified pediatric surgeon with nearly three decades of experience in the field, Mark Holterman, MD, currently serves as a professor at the University of Illinois College of Medicine. Committed to advancing medicine, Dr. Mark Holterman supports the efforts of the American Diabetes Association (ADA). Senior citizens in the United States a higher risk of developing type 2 diabetes, with more than 25 percent of those aged 60 and over living with the disease. That’s why the ADA recently came out in support of a major new initiative known as the Medicare Diabetes Prevention Program (MDPP). This program will serve as an awareness and intervention platform with the goal of reducing the rate of diagnosis by providing support to community providers who, in turn, will be better equipped to provide screening and other services to at-risk communities. The new program will not only help reduce the rate of type 2 diabetes in seniors but will also help deal with rising health care costs that come from treating the illness.
Working at the University of Illinois College of Medicine as a professor of surgery and pediatrics, Dr. Mark Holterman has an interest in the field of biotechnology. Mark Holterman, MD, serves on the board of several organizations, including the Alliance for the Advancement of Cellular Therapies (AACT).One of the leading organizations supporting a Registry of Cell Therapy, AACT believes that establishing a well-curated registry will help address many of the common criticisms about the use of cell therapy, such as concerns about incomplete patient data and the variable quality of stem cells. The proposed registry would also ensure that stem cells are used only for valid treatment strategies according to review board protocols. With a registry, researchers also could address concerns about unreliable data by identifying standardized metrics to apply at uniform points in time by objective observers. Finally, the registry would allow the Food and Drug Administration to audit every aspect of stem cell research data to evaluate safety and efficacy.
